Study Title
An Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients With Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas
Study Details
Description:
Traditional imaging techniques for insulinomas have a low detection rate. This study aims to evaluate the safety, internal radiation dosimetry, and targeted imaging capability of the novel GLP1R imaging agent, 68Ga-DOTA-SEMA, in patients with GLP1R-positive insulinomas.
Sponsor:
The Affiliated Hospital of Southwest Medical University
Contacts:
Xie Yangxy114330@163.com
15183071089
Government Study Link:
NCT06759740 - Click here to see study onClinicalTrials.gov
Drug Details
68Ga-DOTA-SEMA
Isotope(s):
- GALLIUM-68
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- Glucagon-Like Peptide-1 Receptor (GLP1R)
Chelator: DOTA
